Pay-by-results pricing opens up better cancer drugs

By Rachel Nowak in Melbourne Imagine a healthcare system in which drug companies only get paid for a course of treatment if it works as planned. That’s the approach behind a ground-breaking agreement finalised this year between the manufacturer of Velcade, a drug for a type of blood cancer, and the UK’s publicly funded health agencies. The hope is that this agreement, together with a series of other initiatives,
  • 首页
  • 游艇租赁
  • 电话
  • 关于我们